Fig. 2
From: Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
Detection of EGFR mutation by using BALF EV DNA. a. Comparison of EGFR genotyping results performed using tumor tissue, BALF cfDNA, and BALF EV DNA. The top lane indicates EGFR mutation status in the primary tumor tissue of each patient. The second lane shows the result of biopsy of tumor tissues obtained from patients with acquired resistance to EGFR-TKIs. The third and fourth lanes show EGFR mutation status determined by performing liquid biopsy of BALF cfDNA and EV DNA, respectively. Rates of p.T790 M mutation detection by performing tissue rebiopsy and liquid biopsy of BALF cfDNA and BALF EV DNA are shown on the right side of each lane. Abbreviations; E19 del: exon 19 deletion, WT: wild type. b. Diagram showing the contents of an EV. Tumor-derived EVs contain RNA; DNA, including mutant DNA; and proteins